Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial
Authors:
- 1 January 2022
- journal article
- review article
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 16 (1) , 102382
Abstract
No abstract availableKeywords
Funding Information
- Abbott Laboratories
- Kowa Company
- Bayer
- Amgen
- British Heart Foundation (RE/18/6/34217)
- Novartis
- Bristol-Myers Squibb
- University of Glasgow
- Sanofi
- Eli Lilly and Company
- Novo Nordisk
- Boehringer Ingelheim
- Merck Sharp and Dohme United Kingdom
- AstraZeneca
- Pfizer
This publication has 2 references indexed in Scilit:
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsThe Lancet Diabetes & Endocrinology, 2021
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2017